Peer-influenced content. Sources you trust. No registration required. This is HCN.
Cancer Therapy Advisor
Teclistamab, a BCMA bispecific antibody, demonstrates a promising 63% overall response rate in heavily pretreated R/R MM patients, with manageable toxicity compared to CAR T-cell therapy.
Hematology/Oncology June 17th 2024
The New England Journal of Medicine
Secondary malignancies like indolent CD4+ CAR T-cell lymphoma can emerge after CAR T-cell therapy. This case highlights the importance of recognizing and thoroughly investigating these rare complications.
The occurrence of second tumors, such as T-cell lymphomas, post-CAR T-cell therapy is rare. The study identifies Epstein-Barr virus and mutant clonal hematopoiesis as potential factors but finds no evidence of oncogenic retroviral integration, providing valuable insights for clinical practice.
In a recent study involving patients with CD7-positive leukemia and lymphoma, an integrated approach of CAR T-cell therapy followed by haploidentical HSCT resulted in a one-year disease-free survival rate of 54%. This strategy highlights the potential for advanced therapeutic combinations to manage relapsed or refractory hematologic cancers effectively.
Hematology/Oncology April 29th 2024
Explore the potential of CARv3-TEAM-E T cells in recurrent glioblastoma, a novel therapy showing promise with rapid tumor regression and no severe adverse effects in early clinical evaluation.
Oncology, Medical March 18th 2024
With more than 27,000 doses administered, CAR T-cell therapies represent a breakthrough in treating hematologic malignancies, though emerging reports of secondary T-cell cancers post-treatment highlight the importance of long-term patient monitoring and reporting.
Hematology/Oncology February 5th 2024